Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody

Marstacimab

Brand names: Hympavzi

Marstacimab is a monoclonal antibody used as routine prophylaxis to prevent or reduce bleeding episodes in people with haemophilia A or haemophilia B without inhibitors.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It targets tissue factor pathway inhibitor (TFPI), blocking its inhibitory action so that thrombin generation via the tissue factor pathway is enhanced, rebalancing haemostasis independent of factor VIII or IX.

Prescribing in practice

  • As a haemostatic agent it carries a risk of thromboembolic events, so it should be prescribed and supervised by a haemophilia specialist centre.
  • It is given by subcutaneous injection for prophylaxis and is not intended for on-demand treatment of an acute bleed.
  • Care is needed when combining with other haemostatic agents because of the additive thrombotic risk.

Monitoring

Monitor bleeding frequency and remain vigilant for any signs or symptoms of thrombosis.

Counselling the patient

  • This medicine is a regular injection given under the skin to help prevent bleeds.
  • Report symptoms such as limb swelling, chest pain or breathlessness without delay.

Evidence & guidelines

Marstacimab is a non-factor haemophilia therapy regulated through the MHRA; prescribing should follow the approved SPC and specialist guidance.

Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways